Skip to main content

Publication, Part of

[MI] Cancer quality of life survey, Invites up to January 2022

Summary

The Cancer Quality of Life Survey is an ongoing national survey run by the NHS in England. The survey is for people in England who have had a cancer diagnosis, with people invited to complete the survey around 18 months after diagnosis. It has been running since September 2020, with a gradual roll-out to all cancer sites.

The aim of the survey is to find out how quality of life may have changed for people diagnosed with cancer. The survey asks people who have experienced cancer how they are feeling. Their answers will be compared with information about their cancer diagnosis and treatment. This will help the NHS see where care is working well or not so well, and if any new services are needed. It will help the NHS to improve the way it supports people to live as long and as well as possible. The survey is made up of two questionnaires which measure overall health (EQ-5D) and quality of life (EORTC QLQ-C30).

The survey results are reported in an interactive dashboard, including summary score measures and more detailed measures of different aspects of quality of life, including aspects of health (such as mobility), functional categories (such as emotional) and symptoms (such as fatigue). Results are reported by geographies and cancer sites, and with breakdowns by demographic groups.

This release updates the data included in the dashboard, to additionally include data for patients invited from August 2021 to January 2022, and to include response data received up to 24 February 2022.


Key Facts

51% of people with breast, colorectal or prostate cancer who received a survey invite responded

equating to 50,191 responses from the 98,701 people invited

in England, for invites sent between September 2020 and January 2022, including responses up to 24 February 2022

Cancer patients on average scored 75 out of 100, compared to 82 in the general population

for an overall health summary score, where higher scores suggest better quality of life

in England, for invites sent between September 2020 and January 2022, to people who had had breast, colorectal or prostate cancer, including responses up to 24 February 2022 (Overall health summary score, EQ-5D Index)

Background

The data is presented by combinations of selected:

  • Geographies: England, NHS regions and Cancer Alliances.
  • Cancer sites: breast, colorectal and prostate, and all three sites combined.
  • Demographic groups: sex, age at diagnosis, and, for response rate data, ethnic group.

 

Feedback

Feedback can be sent to: NDRSenquiries@nhs.net. This email address can be used for general enquiries to NDRS. Please do not include sensitive or patient identifiable information.



Last edited: 26 April 2022 3:55 pm